Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
124.38
-0.06 (-0.05%)
Nov 20, 2024, 4:00 PM EST - Market closed
Ascendis Pharma Employees
Ascendis Pharma had 879 employees as of December 31, 2023. The number of employees increased by 82 or 10.29% compared to the previous year.
Employees
879
Change (1Y)
82
Growth (1Y)
10.29%
Revenue / Employee
$415,458
Profits / Employee
-$541,158
Market Cap
7.43B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 879 | 82 | 10.29% |
Dec 31, 2022 | 797 | 158 | 24.73% |
Dec 31, 2021 | 639 | 157 | 32.57% |
Dec 31, 2020 | 482 | 152 | 46.06% |
Dec 31, 2019 | 330 | 114 | 52.78% |
Dec 31, 2018 | 216 | 79 | 57.66% |
Dec 31, 2017 | 137 | 36 | 35.64% |
Dec 31, 2016 | 101 | 23 | 29.49% |
Dec 31, 2015 | 78 | 23 | 41.82% |
Dec 31, 2014 | 55 | 10 | 22.22% |
Dec 31, 2013 | 45 | 7 | 18.42% |
Dec 31, 2012 | 38 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Walgreens Boots Alliance | 331,000 |
The Ensign Group | 35,300 |
Chemed | 15,087 |
Bausch + Lomb | 13,300 |
Bruker | 9,707 |
Jazz Pharmaceuticals | 2,800 |
Legend Biotech | 1,826 |
Repligen | 1,783 |
ASND News
- 6 days ago - Ascendis Pharma A/S (ASND) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Ascendis Pharma Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 7 weeks ago - Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency - GlobeNewsWire
- 7 weeks ago - New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024 - GlobeNewsWire
- 2 months ago - Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs - GlobeNewsWire
- 2 months ago - Ascendis Pharma A/S Announces Proposed Public Offering of ADSs - GlobeNewsWire
- 2 months ago - Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year - Benzinga
- 2 months ago - Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo - GlobeNewsWire